Skip to main content
Clinical Trials/EUCTR2020-000112-29-NL
EUCTR2020-000112-29-NL
Active, not recruiting
Phase 1

[18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancer

eiden University Medical Center0 sites15 target enrollmentFebruary 27, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
eiden University Medical Center
Enrollment
15
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 27, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
eiden University Medical Center

Eligibility Criteria

Inclusion Criteria

  • Patients with radiologically FIGO stage IIIB/IIIC EOC based on the conventional CT scan who are
  • scheduled to undergo primary cytoreductive surgery and
  • a)in whom EOC is histologically proven, or
  • b)in whom EOC is cytologically suspected and a serum CA125/CEA ratio \> 25 \[2,22] is found
  • treated with neoadjuvant chemotherapy (NACT) and are scheduled to undergo interval cytoreductive surgery and
  • a)in whom EOC is histologically proven, or
  • b)in whom EOC is cytologically suspected and a serum CA125/CEA ratio \> 25 \[2,22] was found before NACT
  • c)and with radiologically FIGO stage IIIB/IIIC EOC based on the response evaluation CT scan after NACT
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:

Exclusion Criteria

  • 1\. Women younger than 30 years of age (in accordance with the guidelines of the Netherlands Commission on Radiation Dosimetry, as the total radiation dose will be 7\.2 mSv)
  • 2\. Patients who previously underwent primary laparotomy and in whom complete or optimal cytoreduction was not considered feasible.
  • 3\. Contraindication for PET (pregnancy, lactating or severe claustrophobia)
  • 4\. Impaired renal function (defined as eGFR \< 50 mL/1\.73 m2\)
  • 5\. Impaired liver function (ALT, AST or total bilirubin \> 3x upper limit of normal)
  • 6\. Clinically significant abnormalities on ECG and/or clinically laboratory test
  • 7\. Inability to tolerate lying supine for the duration of a PET/CT examination (\~110 minutes)
  • 8\. Patients with concomitant malignancy (except basal cell carcinoma of the skin) or any condition that in the opinion of the investigators could potentially jeopardize the health status of the patient
  • 9\. Patients not able to comply with the study procedures
  • 10\. Patients who did not give informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials